BG-12 results from DEFINE study in Multiple Sclerosis will be presented by Biogen at ECTRIMS and ACTRIMS conference

Phase III DEFINE clinical trial of oral BG-12 (dimethyl fumarate) from Biogen-IDEC was performed in people with relapsing-remitting multiple sclerosis (RRMS). Results showed that 240 mg of BG-12, administered either twice a day (BID) or three times a day (TID), significantly reduced the proportion of patients who relapsed by 49 percent and 50 percent, respectively, at two years compared with placebo. Detailed data from DEFINE will be presented at the 5th Joint Triennial Congress of the European and Americas Committees on Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS) in Amsterdam.